SCHEMBL3167389

SCHEMBL3167389

C=CCCc1ccc2cc(-c3ccc(-c4cc(F)cc(F)c4)cc3)ccc2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 3/20 0.42
CYP11B1 P15538 3/20 0.42
CYP21A2 P08686 1/20 0.42
PGR P06401 1/20 0.38
HRH3 Q9Y5N1 9/20 0.37
TAAR1 Q96RJ0 2/20 0.36
SLC6A2 P23975 1/20 0.35
SLC6A4 P31645 1/20 0.35
SLC6A3 Q01959 1/20 0.35
KCNH2 Q12809 1/20 0.35
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
RXRA P19793 1/20 0.32
RXRB P28702 1/20 0.32
RXRG P48443 1/20 0.32
CYP3A4 P08684 2/20 0.32
CYP11B2 P19099 2/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
FGFR1 P11362 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3163644 0.98 CYP17A1 (0.40) CYP17A1CYP11B1CYP21A2PGRHRH3
SCHEMBL3165954 0.91 MAOB (0.40) CYP17A1CYP11B1CYP21A2PGRHRH3
SCHEMBL3168235 0.91 MAOB (0.40) CYP17A1CYP11B1CYP21A2PGRHRH3
SCHEMBL3167458 0.90 CYP17A1 (0.35) CYP17A1CYP11B1CYP21A2PGRHRH3
SCHEMBL3160592 0.88 TAAR1 (0.51) CYP17A1CYP11B1CYP21A2HRH3TAAR1
SCHEMBL6058651 0.88 ESR1 (0.37) CYP17A1CYP11B1CYP21A2PGRHRH3
SCHEMBL3167430 0.87 HRH3 (0.42) CYP17A1CYP11B1HRH3CYP3A4CYP11B2
SCHEMBL3167005 0.87 TAAR1 (0.49) CYP17A1CYP11B1TAAR1SLC6A2SLC6A4
SCHEMBL3262256 0.87 ESR1 (0.37) CYP17A1CYP11B1CYP21A2HRH3TAAR1
SCHEMBL3153357 0.85 ESR1 (0.38) CYP17A1CYP11B1HRH3TAAR1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1452514-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-09-01 EP claimed
EP-1452514-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2010-03-31 EP disclosed
EP-1273562-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2009-07-22 EP disclosed
US-7145047-B2 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-12-05 US disclosed
EP-1452514-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-09-01 EP disclosed
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-07-24 US disclosed
EP-1273562-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-01-08 EP disclosed
US-6468607-B1 MISCIBILITY, LARGE BIREFRINGENCE INDEX, NO STRONGLY POLAR GROUP IN ITS MOLECULE AND THUS CAN ALSO BE USED FOR ACTIVE MATRIX DRIVING, WIDE TEMPERATURE RANGE AND REQUIRES A HIGH SPEED RESPONSE AND A LOW VOLTAGE DRIVING DAINIPPON INK AND CHEMICALS, INC. (JP) 2002-10-22 US disclosed
EP-0952135-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same NLK, NOTCH1, NOTCH4 CYP17A1 425/4885CYP11B1 1455/4885CYP21A2 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.